INDUSTRY: Health Tech

​

SECTOR: Digital CRO

​

VERTICAL: Health data solutions for clinical trials for innovative drugs

​

BUSINESS MODEL: Digital biomarkers to monitor the evolution of serious and debilitating diseases in neuroscience (multiple sclerosis, etc.), neuromuscular diseases (myasthenia gravis, etc.), rare diseases (cystic fibrosis, etc.) and mental disorders (resistant depression, etc.) in the context of Phase III-IV clinical trials

​

GROWTH INITIATIVES: Enlargement of the solutions to new diseases, and expansion into later Phase IV positioning

​

INVESTMENT DATE: 2025

​

LOCATION: France (Paris, 75)

AdScientiam is a company specializing in digital biomarkers dedicated to the continuous, real-life monitoring of serious and debilitating diseases. It helps optimizing the cost of monitoring the evolution of these diseases with patients in real-life conditions. Its flagship product, MSCopilot®, is a CE-marked software medical device dedicated to the self-assessment of multiple sclerosis in real-world conditions, and is being expanded to other diseases.

​

The mobile app collects more than 350 digital biomarkers via smartphone and returns the data to healthcare professional via a secure dashboard. MSCopilot® is integrated with several clinical studies as well.

​

AdScientiam collaborates with big pharma companies in the context of the launches of innovative drugs.

​

​